Pinnacle Associates Ltd. cut its stake in Atara Biotherapeutics, Inc. (NASDAQ: ATRA – Get Rating) by 7.1% in Q3, according to its latest SEC filing. The fund held 398,414 shares of the biotech company after selling 30,293 shares during the period. Pinnacle Associates Ltd. owned 0.42% of Atara Biotherapeutics worth $1,506,000 when it last filed with the SEC.
Several other hedge funds and other institutional investors have also recently changed their ATRA holdings. US Bancorp DE increased its position in Atara Biotherapeutics shares by 6,394.9% in the third quarter. US Bancorp DE now owns 7,664 shares of the biotech company worth $29,000 after buying 7,546 additional shares in the last quarter. Diversified Trust Co bought a new stake in shares of Atara Biotherapeutics in Q3 for a value of approximately $48,000. Wealth Architects LLC purchased a new stake in Atara Biotherapeutics stock in Q3 for approximately $50,000. Denali Advisors LLC purchased a new stake in Atara Biotherapeutics stock in Q3 for approximately $50,000. Finally, Point72 Hong Kong Ltd increased its position in Atara Biotherapeutics shares by 343.8% in the 1st quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotech company worth $67,000 after buying an additional 5,604 shares in the last quarter.
Insider Buying and Selling at Atara Biotherapeutics
In other Atara Biotherapeutics news, Chief Financial Officer Utpal Koppikar sold 6,255 shares of the company in a trade dated Wednesday, November 16. The shares were sold at an average price of $4.49, for a total transaction of $28,084.95. Following completion of the transaction, the CFO now directly owns 191,334 shares of the company, valued at approximately $859,089.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 15,591 shares of the company in a trade dated Wednesday, November 16. The shares were sold at an average price of $4.49, for a total transaction of $70,003.59. Following the sale, the CEO now directly owns 441,696 shares of the company, valued at approximately $1,983,215.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this link. Additionally, CFO Utpal Koppikar sold 6,255 shares of the company in a trade dated Wednesday, November 16. The stock was sold at an average price of $4.49, for a total transaction of $28,084.95. Following the sale, the CFO now owns 191,334 shares of the company, valued at $859,089.66. The disclosure of this sale can be found here. Insiders sold 29,800 shares of the company valued at $133,802 in the past ninety days. Insiders of the company own 4.00% of the shares of the company.
Wall Street analysts predict growth
ATRA has been the subject of several research analyst reports. StockNews.com launched coverage on Atara Biotherapeutics shares in a Wednesday, October 12 research report. They issued a “hold” rating for the company. EF Hutton Acquisition Co. I initiated stock coverage of Atara Biotherapeutics in a Thursday, January 5 report. They issued a “buy” rating and a price target of $25.00 for the company. Two investment analysts have assigned the stock a sell rating, three have assigned a hold rating and three have assigned the company’s stock a buy rating. According to MarketBeat.com, Atara Biotherapeutics currently has an average rating of “Hold” and an average target price of $19.50.
Atara Biotherapeutics stock performance
The NASDAQ ATRA opened at $3.89 on Friday. The company has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $4.34. The company has a market capitalization of $369.08 million, a PE ratio of -1.57 and a beta of 1.08. Atara Biotherapeutics, Inc. has a one-year low of $2.83 and a one-year high of $16.35.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last reported results on Tuesday, November 8. The biotech company reported ($0.82) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.78) by ($0.04). The company posted revenue of $4.46 million for the quarter, versus analyst estimates of $4.37 million. Atara Biotherapeutics had a negative net margin of 348.49% and a negative return on equity of 125.38%. Stock analysts expect Atara Biotherapeutics, Inc. to post earnings per share of -2.15 for the current year.
Atara Biotherapeutics Company Profile
(Get an evaluation)
Atara Biotherapeutics, Inc, a ready-to-use T-cell immunotherapy company, is developing treatments for patients with cancer, autoimmune and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is in Phase 3 clinical trials for the treatment of Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative disease, as well as hematological tumors and solids, including nasopharyngeal carcinoma.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to email@example.com.
Before you consider Atara Biotherapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Atara Biotherapeutics was not on the list.
While Atara Biotherapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here